P62 Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.080
https://www.valueinhealthjournal.com/article/S1098-3015(22)00281-9/fulltext
Title : P62 Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00281-9&doi=10.1016/j.jval.2022.04.080
First page :
Section Title :
Open access? : No
Section Order : 10063
Categories :
Tags :
Regions :
ViH Article Tags :